NCT03541005

Evaluation of Obex® in Overweight and Obesity

Efficacy and Safety of the Obex® Nutritional Supplement in Overweight and Obese Subjects: Phase III.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 160 (actual)
• Sponsor: Catalysis SL · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

* Obesity is an important and growing worldwide * Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer * Diverse adverse events have been reported with the use of antiobesity drugs. * Several articles describe the beneficial effect of several specific components of the Obex® supplement on weight loss, in the reduction of waist circumference, suppression of appetite, decrease fasting glucose levels, improvement of insulin sensitivity and β cells function. * Therefore, the administration of Obex in overweight and obese patients could be an excellent strategy to induce weight loss and ameliorate the metabolic disturbances related to obesity and overweight.

Conditions

• Overweight and Obesity

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Obex	After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex
DIETARY_SUPPLEMENT	Placebo	After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.

Timeline

• Start date: 2018-10-01
• Primary completion: 2019-09-01
• Completion: 2021-07-03
• First posted: 2018-05-30
• Last updated: 2021-10-21

Locations

1 site across 1 country: Cuba